Novo Nordisk A/S — Form 6-K
Filing date: October 2, 2026. The filing reports an update on the U.S. FDA review of denecimig for haemophilia A; it does not cover a financial reporting period.
Business context and regulatory update
Denecimig is an investigational subcutaneous treatment intended to prevent bleeding episodes in adults and children with haemophilia A, with or without inhibitors. Novo submitted its U.S. BLA in September 2025. The FDA review remains ongoing, and the agency has not provided a revised date for regulatory action.
- The FDA said facility remediation activities are extending its review following feedback from a pre-license inspection.
- Novo said the FDA has not identified deficiencies in the clinical efficacy or safety data from the FRONTIER programme.
- Novo is working with the FDA to address the outstanding manufacturing-facility requirements. The company said the facility feedback does not affect its other marketed products.
- Denecimig received a positive CHMP opinion on September 17, 2026, and is awaiting EMA marketing approval; it is also under review by other regulatory authorities.
Financial metrics and outlook
The filing provides no revenue, profit, cash flow, margin, debt, or liquidity figures. Novo stated that the extended FDA review does not affect its 2026 financial outlook.
Changes, outlook, and risks
The previously anticipated U.S. regulatory decision was in the third quarter of 2026. The FDA review extension means that timing is no longer specified; Novo did not provide a replacement decision date. Subject to a regulatory decision, Novo aims to launch denecimig in the U.S. in the first half of 2027.
The principal disclosed uncertainty is the timing and completion of facility remediation and the resulting FDA review. The filing reports no clinical efficacy or safety data deficiency identified by the FDA, but does not guarantee approval or launch timing.
Key facts for investors to verify
- Whether Novo completes the FDA-requested facility remediation and satisfies the agency’s outstanding requirements.
- Whether the FDA provides a new review timeline or regulatory decision.
- Whether the EMA and other regulators grant marketing approval.
- Whether the U.S. launch target of the first half of 2027 remains achievable.
- Whether any subsequent update changes the stated 2026 financial outlook or the status of other marketed products.